medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2024, Number 06

<< Back

Ginecol Obstet Mex 2024; 92 (06)

Nonavalent vaccine against human papillomavirus: a strategy to prevent cervical cancer

Anaya RAF

Language: Spanish
References: 33
Page: 267-273
PDF size: 208.61 Kb.


ABSTRACT

Background: Cervical cancer is a public health problem due to its high incidence. Its main cause is the human papillomavirus transmitted by sexual contact. One prevention tool is immunization. At present there are three vaccines, the nonavalent is the most recent.
Objective: To investigate the recent literature and describe the findings with the application of the nonavalent vaccine in patients with cervical cancer.
Methodology: Search of articles in the Pubmed database with the descriptor “nonavalent” and the MeSH terms “recombinant nonavalent human papillomavirus vaccine”, “human papillomavirus vaccines” and “cervical cancer”; the above with adverse reactions, effectiveness and impact of the nonavalent vaccine against cervical cancer.
Results: We found 107 articles of which 80 were excluded due to duplicates, confusing titles and incomplete abstracts, without providing data related to the study. In the end, only 27 sources were analyzed.
Conclusions: The nonavalent vaccine has reach against five high-risk genotypes; more than other vaccines. It is effective against diseases caused by human papillomavirus, including cervical intraepithelial neoplasia and cervical cancer. In addition, it has a safety profile similar to that of its predecessor vaccines, although its effectiveness is linked to other factors.


REFERENCES

  1. Harden ME, Munger K. Human papillomavirus molecularbiology. Mutat Res - Rev Mut Res 2017; 772: 3-12. https://doi.org/10.1016/j.mrrev.2016.07.002

  2. Gravitt P, Winer R. Natural history of HPV infection acrossthe lifespan: role of viral latency. Viruses 2017; 9: 267.http://dx.doi.org/10.3390/v9100267

  3. Graham SV. The human papillomavirus replication cycle,and its links to cancer progression: a comprehensivereview. Clin Sci 2017; 131 (17): 2201-21. https://doi.org/10.1042/CS20160786

  4. Buskwofie A, David-West G, Clare CA. A Review ofCervical Cancer: Incidence and Disparities. J Natl MedAssoc 2020; 112 (2): 229-32. https://doi.org/10.1016/j.jnma.2020.03.002

  5. Vu M, Yu J, Awolude OA, et al. Cervical cancer worldwide.Curr Probl Cancer 2018; 42 (5): 457-65. https://doi.org/10.1016/j.currproblcancer.2018.06.003

  6. Yousefi Z, Aria H, Ghaedrahmati F, Bakhtiari T, et al. AnUpdate on human papilloma virus vaccines: History, types,protection and efficacy. Front Immunol 2022; 12. http://dx.doi.org/10.3389/fimmu.2021.805695

  7. Aranda-Flores CE. Infección por el virus del papiloma humanoen varones. Ginecol Obstet Mex 2015; 83: 697-706.https://ginecologiayobstetricia.org.mx/articulo/infeccionpor-el-virus-del-papiloma-humano-en-varones

  8. Lazcano-Ponce E, Salmerón J, González A, et al. Preventionand control of neoplasms associated with HPV in high-riskgroups in Mexico City: The Condesa Study. Salud PublicaMex 2018; 60 (6): 703-12. https://doi.org/10.21149/10034

  9. Johnson CA, James D, Marzan A, Armaos M. Cervicalcancer: an overview of pathophysiology and management.Semin Oncol Nurs 2019; 35 (2): 166-74. https://doi.org/10.1016/j.soncn.2019.02.003

  10. Durham DP, Ndeffo-Mbah ML, Skrip LA, Jones FK, et al.National and state-level impact and cost-effectivenessof nonavalent HPV vaccination in the United States. ProcNatl Acad Sci USA 2016; 113 (18): 5107-12. https://doi.org/10.1073/pnas.1515528113

  11. Boiron L, Joura E, Largeron N, Prager B, et al. Estimatingthe cost-effectiveness profile of a universal vaccinationprogramme with a nine-valent HPV vaccine in Austria.BMC Infect Dis 2016; 16: 153. https://doi.org/10.1186/s12879-016-1483-5

  12. Forster AS, Waller J. Taking stock and looking ahead: Behaviouralscience lessons for implementing the nonavalenthuman papillomavirus vaccine. Eur J Cancer 2016; 62: 96-102. https://doi.org/10.1016/j.ejca.2016.04.014

  13. Riethmuller D, Jacquard AC, Lacau St Guily J, Aubin F, etal. Potential impact of a nonavalent HPV vaccine on theoccurrence of HPV-related diseases in France. BMC PublicHealth 2015; 15: 453. https://doi.org/10.1186/s12889-015-1779-1

  14. Serrano B, Alemany L, Alonso de Ruiz P, Tous S, et al. Potentialimpact of a 9-valent HPV vaccine in HPV-related cervicaldisease in 4 emerging countries (Brazil, Mexico, India andChina). Cancer Epidemiology 2014; (38): 748-56. https://doi.org/10.1016/j.canep.2014.09.003

  15. Egli-Gany D, Spaar Zographos A, Diebold J, Masserey SpicherV, et al. Human papillomavirus genotype distributionand socio-behavioural characteristics in women with cervicalpre-cancer and cancer at the start of a human papillomavirusvaccination programme: the CIN3+ plus study.BMC Cancer 2019; 19 (1): 111. https://doi.org/10.1186/s12885-018-5248-y

  16. Inturrisi F, Lissenberg-Witte BI, Veldhuijzen NJ, Bogaards JA,et al. Estimating the direct effect of human papillomavirusvaccination on the lifetime risk of screen-detected cervicalprecancer. Int J Cancer 2021; 148 (2): 320-28. https://doi.org/10.1002/ijc.33207

  17. Capra G, Giovannelli L, Matranga D, Bellavia C, et al. Potentialimpact of a nonavalent HPV vaccine on HPV relatedlow-and high-grade cervical intraepithelial lesions: A referral hospital-based study in Sicily. Hum Vaccin Immunother2017; 13 (8): 1839-43. https://doi.org/10.1080/21645515.2017.1319026

  18. Petry KU, Bollaerts K, Bonanni P, Stanley M, et al. Estimationof the individual residual risk of cervical cancer aftervaccination with the nonavalent HPV vaccine. Hum VaccinImmunother 2018; 14 (7): 1800-6. https://doi.org/10.1080/21645515.2018.1450125

  19. Mariani L, Preti M, Cristoforoni P, Stigliano CM, et al. Overviewof the benefits and potential issues of the nonavalentHPV vaccine. Int J Gynaecol Obstet 2017; 136 (3): 258-65.https://doi.org/10.1002/ijgo.12075

  20. Ng SS, Hutubessy R, Chaiyakunapruk N. Systematic reviewof cost-effectiveness studies of human papillomavirus(HPV) vaccination: 9-Valent vaccine, gender-neutral andmultiple age cohort vaccination. Vaccine 2018; 36 (19):2529-44. https://doi.org/10.1016/j.vaccine.2018.03.024

  21. Chesson HW, Laprise JF, Brisson M, Markowitz LE. Impactand cost-effectiveness of 3 doses of 9-valent human papillomavirus(HPV) vaccine among US females previouslyvaccinated with 4-Valent HPV Vaccine. J Infect Dis 2016;213 (11): 1694-700. https://doi.org/10.1093/infdis/jiw046

  22. Lopalco PL. Spotlight on the 9-valent HPV vaccine. DrugDes Devel Ther. 2017; 11: 35-44. https://doi.org/10.2147/DDDT.S91018

  23. Mahumud RA, Alam K, Dunn J, Gow J. The cost-effectivenessof controlling cervical cancer using a new 9-valenthuman papillomavirus vaccine among school-aged girls inAustralia. PLoS One 2019; 14 (10): e0223658. https://doi.org/10.1371/journal.pone.0223658

  24. Michaeli DT, Stoycheva S, Marcus SM, Zhang W, et al. Costeffectivenessof bivalent, quadrivalent, and nonavalent HPVVaccination in South Africa. Clin Drug Investig 2022; 42(4): 333-43. https://doi.org/10.1007/s40261-022-01138-6

  25. Jiang Y, Ni W, Wu J. Cost-effectiveness and value-basedprices of the 9-valent human papillomavirus vaccine forthe prevention of cervical cancer in China: an economicmodelling analysis. BMJ Open 2019; 9 (11): e031186.https://doi.org/10.1136/bmjopen-2019-031186

  26. Phua LC, Choi HCW, Wu J, Jit M, et al. Cost-effectivenessanalysis of the nonavalent human papillomavirus vaccinefor the prevention of cervical cancer in Singapore. Vaccine.2022; 39 (16): 2255-63. https://doi.org/10.1016/j.vaccine.2021.03.040

  27. Naslazi E, Hontelez JAC, Naber SK, van Ballegooijen M, etal. The differential risk of cervical cancer in HPV-vaccinatedand -unvaccinated women: a mathematical modelingstudy. Cancer Epidemiol Biomarkers Prev 2021; 30 (5):912-19. https://doi.org/10.1158/1055-9965.EPI-20-1321

  28. De la Fuente J, Aguado JJH, Martín MS, Boix PR, et al. Estimatingthe epidemiological impact and cost-effectivenessprofile of a nonavalent HPV vaccine in Spain. HumanVaccines & Immunotherapeutics 2019; 15 (7-8) 1949–61.http://dx.doi.org/10.1080/21645515.2018.1560770

  29. Simms KT, Smith MA, Lew JB, Kitchener HC, et al. Will cervicalscreening remain cost-effective in women offered thenext generation nonavalent HPV vaccine? Results for fourdeveloped countries. Int J Cancer 2016; 139 (12): 2771-80.https://doi.org/10.1002/ijc.30392

  30. Joura EA, Giuliano AR, Iversen OE, Bouchard C, et al. A9-valent HPV vaccine against infection and intraepithelialneoplasia in women. N Engl J Med 2015; 372 (8): 711-23.https://doi.org/10.1056/NEJMoa1405044

  31. Toh ZQ, Kosasih J, Russell FM, Garland SM, et al. Recombinanthuman papillomavirus nonavalent vaccine in the preventionof cancers caused by human papillomavirus. InfectDrug Resist 2019; 12: 1951-67. https://doi.org/10.2147/IDR.S178381

  32. Logroño IEN, Macías ACC, Macías LGC. Eficacia de la vacunanonavalente en la prevención de la infección por virus papilomahumano (HPV) y cáncer cervical. La Ciencia al Serviciode la Salud 2019; 9 (2): 30-7. http://revistas.espoch.edu.ec/index.php/cssn/article/view/88

  33. Kharbanda EO, Vazquez-Benitez G, DeSilva MB, NalewayAL, et al. Association of inadvertent 9-valent human papillomavirusvaccine in pregnancy with spontaneous abortionand adverse birth outcomes. JAMA Netw Open 2021; 4 (4):e214340. https://doi.org/10.1001/jamanetworkopen.2021




2020     |     www.medigraphic.com